Type 3 hypersensitivity in COVID-19 vasculitis.
Aged
Antibodies, Viral
/ biosynthesis
Antigen-Antibody Complex
/ biosynthesis
Betacoronavirus
/ immunology
Blood Vessels
/ immunology
COVID-19
Complement C3
/ biosynthesis
Coronavirus Infections
/ complications
Cytokine Release Syndrome
/ complications
Disease Progression
Endothelial Cells
/ immunology
Humans
Immune Complex Diseases
/ complications
Immunity, Humoral
Immunoglobulin G
/ biosynthesis
Immunoglobulin M
/ biosynthesis
Interleukin-6
/ biosynthesis
Male
Pandemics
Pneumonia, Viral
/ complications
SARS-CoV-2
Severe Acute Respiratory Syndrome
/ complications
Th2 Cells
/ immunology
Vasculitis
/ complications
Coronavirus disease 2019 (COVID-19)
Immune complex disease
Interleukin-6 (IL-6)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Type III hypersensitivity
Vasculitis
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
23
05
2020
revised:
26
05
2020
accepted:
27
05
2020
pubmed:
2
6
2020
medline:
22
7
2020
entrez:
2
6
2020
Statut:
ppublish
Résumé
Coronavirus Disease 2019 (COVID-19) is an ongoing public health emergency and new knowledge about its immunopathogenic mechanisms is deemed necessary in the attempt to reduce the death burden, globally. For the first time in worldwide literature, we provide scientific evidence that in COVID-19 vasculitis a life-threatening escalation from type 2 T-helper immune response (humoral immunity) to type 3 hypersensitivity (immune complex disease) takes place. The subsequent deposition of immune complexes inside the vascular walls is supposed to induce a severe inflammatory state and a cytokine release syndrome, whose interleukin-6 is the key myokine, from the smooth muscle cells of blood vessels.
Identifiants
pubmed: 32479986
pii: S1521-6616(20)30452-6
doi: 10.1016/j.clim.2020.108487
pmc: PMC7256503
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Antigen-Antibody Complex
0
Complement C3
0
IL6 protein, human
0
Immunoglobulin G
0
Immunoglobulin M
0
Interleukin-6
0
Types de publication
Case Reports
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
108487Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None of the authors has any financial conflict of interest to disclose.
Références
Ann Hematol. 2020 Jun;99(6):1419-1420
pubmed: 32382776
Clin Immunol. 2020 Jun;215:108450
pubmed: 32360516
Arthritis Res Ther. 2007;9 Suppl 2:S9
pubmed: 17767747
Med Hypotheses. 2020 Sep;142:109824
pubmed: 32408068
Med Hypotheses. 2020 Mar 21;140:109686
pubmed: 32220710
Clin Infect Dis. 2001 Jan;32(1):76-102
pubmed: 11118387
J Med Virol. 2006 Jan;78(1):1-8
pubmed: 16299724
Lancet. 2003 May 24;361(9371):1767-72
pubmed: 12781535
Arterioscler Thromb Vasc Biol. 2012 Jan;32(1):103-9
pubmed: 22034510
Br J Haematol. 2020 Jun;189(5):846-847
pubmed: 32304577